Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological MalignanciesMauricette Michallet, Franck‐Emmanuel Nicolini, Mohamad Sobh et al.|Blood|2016Cited by 4
Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated DonorsMauricette Michallet, Franck‐Emmanuel Nicolini, Fiorenza Barraco et al.|Blood|2016Cited by 2
Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete RemissionMauricette Michallet, Franck E. Nicolini, Mohamad Sobh et al.|Blood|2015Cited by 1
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different OutcomesStéphanie Ducreux, Valérie Dubois, Mohamad Sobh et al.|Blood|2015Cited by 1
First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological MalignanciesMauricette Michallet, Franck E. Nicolini, Mohamad Sobh et al.|Blood|2015Cited by 0